Tags

Type your tag names separated by a space and hit enter

Baroreflex activation therapy: a new treatment option for heart failure with reduced ejection fraction.
Expert Rev Cardiovasc Ther. 2014 Dec; 12(12):1465-9.ER

Abstract

Sympathovagal imbalance plays a major role in the progression of heart failure with reduced ejection fraction. Baroreflex activation therapy (BAT) by electrical stimulation of baroreceptors located at the carotid sinus can reduce sympathetic and increase parasympathetic tone. This review provides an overview on the concept of BAT in heart failure with reduced ejection fraction and available preclinical and clinical data. Animal studies of BAT in heart failure with reduced ejection fraction have demonstrated a decline in plasma norepinephrine, an improved left ventricular ejection fraction, a reduced susceptibility to induced ventricular arrhythmias and a survival benefit. First clinical data from uncontrolled studies suggest a relevant improvement in muscle sympathetic nerve activity, ejection fraction, 6-min walk distance, New York Heart Association (NYHA) class and hospitalization rate. BAT appears to be safe in this severely ill patient population.

Authors+Show Affiliations

Department of Internal Medicine III, Heart Center, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

25382103

Citation

Halbach, Marcel, et al. "Baroreflex Activation Therapy: a New Treatment Option for Heart Failure With Reduced Ejection Fraction." Expert Review of Cardiovascular Therapy, vol. 12, no. 12, 2014, pp. 1465-9.
Halbach M, Hickethier T, Madershahian N, et al. Baroreflex activation therapy: a new treatment option for heart failure with reduced ejection fraction. Expert Rev Cardiovasc Ther. 2014;12(12):1465-9.
Halbach, M., Hickethier, T., Madershahian, N., & Müller-Ehmsen, J. (2014). Baroreflex activation therapy: a new treatment option for heart failure with reduced ejection fraction. Expert Review of Cardiovascular Therapy, 12(12), 1465-9. https://doi.org/10.1586/14779072.2014.979790
Halbach M, et al. Baroreflex Activation Therapy: a New Treatment Option for Heart Failure With Reduced Ejection Fraction. Expert Rev Cardiovasc Ther. 2014;12(12):1465-9. PubMed PMID: 25382103.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Baroreflex activation therapy: a new treatment option for heart failure with reduced ejection fraction. AU - Halbach,Marcel, AU - Hickethier,Tilman, AU - Madershahian,Navid, AU - Müller-Ehmsen,Jochen, Y1 - 2014/11/10/ PY - 2014/11/11/entrez PY - 2014/11/11/pubmed PY - 2015/9/2/medline KW - baroreceptor KW - baroreflex activation therapy KW - heart failure KW - interventional treatment KW - review SP - 1465 EP - 9 JF - Expert review of cardiovascular therapy JO - Expert Rev Cardiovasc Ther VL - 12 IS - 12 N2 - Sympathovagal imbalance plays a major role in the progression of heart failure with reduced ejection fraction. Baroreflex activation therapy (BAT) by electrical stimulation of baroreceptors located at the carotid sinus can reduce sympathetic and increase parasympathetic tone. This review provides an overview on the concept of BAT in heart failure with reduced ejection fraction and available preclinical and clinical data. Animal studies of BAT in heart failure with reduced ejection fraction have demonstrated a decline in plasma norepinephrine, an improved left ventricular ejection fraction, a reduced susceptibility to induced ventricular arrhythmias and a survival benefit. First clinical data from uncontrolled studies suggest a relevant improvement in muscle sympathetic nerve activity, ejection fraction, 6-min walk distance, New York Heart Association (NYHA) class and hospitalization rate. BAT appears to be safe in this severely ill patient population. SN - 1744-8344 UR - https://www.unboundmedicine.com/medline/citation/25382103/Baroreflex_activation_therapy:_a_new_treatment_option_for_heart_failure_with_reduced_ejection_fraction_ L2 - http://www.tandfonline.com/doi/full/10.1586/14779072.2014.979790 DB - PRIME DP - Unbound Medicine ER -